The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

The International Journal of Vascular Medicine is a peer-reviewed, open access journal dedicated to advancing research and knowledge in the field of vascular medicine. Published by HINDAWI LTD and operating since 2010, this journal provides a platform for the dissemination of high-quality studies, reviews, and case reports related to cardiovascular health. Based in Egypt, the journal's comprehensive scope encompasses a range of topics within cardiology and cardiovascular medicine, with a current impact factor reflected by its Q3 ranking in 2023, positioning it among the noteworthy publications in its category. With a Scopus rank of 176 out of 387, the journal maintains a significant presence in the academic community, supported by a commitment to open access, ensuring that research is freely available to all stakeholders. Researchers, professionals, and students alike are encouraged to contribute to and engage with the International Journal of Vascular Medicine as it enhances the understanding and treatment of vascular diseases and promotes innovative practices within the field.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Welcome to the JOURNAL OF VASCULAR RESEARCH, a reputable academic journal published by KARGER that has been a cornerstone of vascular research since 1964. With an ISSN of 1018-1172 and an E-ISSN of 1423-0135, this journal plays a vital role in disseminating cutting-edge research in the fields of Cardiology and Cardiovascular Medicine and Physiology. Currently categorized in the Q3 quartile for both disciplines, it ranks as #179 in Cardiology and #131 in Physiology according to Scopus, showcasing its significant contribution to the scientific community. Although the journal operates on a subscription basis, it strives to provide accessible content that informs and inspires researchers, professionals, and students alike. As the journal looks forward to its convergence in 2024, it continues to uphold its mission of advancing knowledge, fostering innovation, and encouraging collaboration within the dynamic realm of vascular research.

Acta Angiologica, published by VIA MEDICA, is an Open Access journal dedicated to the dynamic field of cardiology and cardiovascular medicine. Since its inception in 1995, this esteemed journal has provided a vital platform for the dissemination of cutting-edge research and innovative medical practices, especially pertinent to vascular health. Being indexed in Scopus, it holds a rank of #352 out of 387 in its category for 2023, positioning it in the 9th percentile among contemporaneous journals. The journal's commitment to scholarly excellence and accessibility is underscored by its embrace of open access publishing, allowing researchers, professionals, and students to engage with vital advancements in the field without financial barriers. With a converged timeline from 2005 to 2024, Acta Angiologica continues to play a crucial role in bridging gaps in cardiovascular knowledge, fostering collaboration across disciplines, and advancing the implementation of preventative and therapeutic strategies in vascular medicine. Located in Gdansk, Poland, the journal is poised to make significant contributions to the cardiovascular research landscape.

ANGIOLOGY is a leading journal dedicated to the field of cardiology and cardiovascular medicine, published by SAGE Publications Inc. With a distinguished history dating back to 1950, this journal serves as an essential platform for the dissemination of cutting-edge research, innovative clinical practices, and emerging trends in cardiovascular health. Holding a respected Q2 ranking in the 2023 Scopus category for Cardiology and Cardiovascular Medicine, and positioned within the 74th percentile of its field, ANGIOLOGY is an invaluable resource for researchers, healthcare professionals, and students alike. While currently not an open-access journal, it offers subscription options to access comprehensive articles that aim to advance knowledge and improve patient care across various cardiovascular disciplines. The journal's commitment to fostering dialogue and sharing groundbreaking findings underscores its importance in the ongoing pursuit of cardiovascular excellence.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

Arterial Hypertension is a dedicated Open Access journal published by VIA MEDICA, with the ISSN 2449-6170 and E-ISSN 2449-6162, focusing on the multidisciplinary field of cardiology, endocrinology, and internal medicine. Established in Poland, this journal has been providing researchers and healthcare professionals with accessible, high-quality content since its inception in 1999. With a commitment to advancing knowledge in the management and treatment of arterial hypertension, it publishes significant research findings, clinical trials, and reviews that contribute to improved health outcomes. Though classified in Q4 across various relevant categories, the continuous improvement in its content ensures its relevance in an evolving medical landscape. Designed to facilitate collaboration and innovation, Arterial Hypertension serves as a crucial resource for anyone invested in cardiovascular health, encouraging open dialogue and dissemination of vital research within the scientific community.